Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 October 2022, including: Bristol Myers Squibb Company looks to new launches amid patent losses; Novartis AG prioritizes high-value medicines and the US market; Biogen, Inc. learns from Aduhelm experience; Johnson & Johnson builds myeloma franchise; and Asian bioventures debate best strategies.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "All Eyes On Bristol's New Launches" - Scrip, 26 Oct, 2022.)

(Also see "Weak Spots Blight Novartis Third Quarter As New Products Shine" - Scrip, 25 Oct, 2022.)

(Also see "Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch" - Scrip, 25 Oct, 2022.)

(Also see "J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval" - Scrip, 26 Oct, 2022.)

(Also see "How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders" - Scrip, 24 Oct, 2022.)

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel